Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

PHASE4CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

irinotecan

180 mg/m² or 260 mg/m² in 90 minutes every 15 days

DRUG

5 fluorouracil

400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion

Trial Locations (6)

38043

Department of Oncology, CHU, Grenoble

38100

Department of Oncology, IPC, Grenoble

42271

Department of Oncology, ICL, Saint-Priest-en-Jarez

69310

Department of Gastroenterology, CHLS, Pierre-Bénite

Department of Oncology - CHLS, Pierre-Bénite

Unknown

Institut Claudius Regaud, Toulouse

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Institut de Recherche Clinique sur les Cancers et le Sang

OTHER